Literature DB >> 7603530

Glycogenosis type II (acid maltase deficiency).

A J Reuser1, M A Kroos, M M Hermans, A G Bijvoet, M P Verbeet, O P Van Diggelen, W J Kleijer, A T Van der Ploeg.   

Abstract

Glycogen storage disease type II (GSD II/glycogenosis type II/Pompe's disease/acid maltase deficiency) is caused by the deficiency of lysosomal alpha-glucosidase resulting in lysosomal accumulation of glycogen. The disease is inherited as an autosomal recessive trait and is clinically heterogeneous. Early and late onset phenotypes are distinguished. Insight in the molecular nature of the lysosomal alpha-glucosidase deficiency and the underlying genetic defect has increased significantly during the past decade. This minireview on GSD II was written at the occasion of The International Symposium on Glycolytic and Mitochondrial Defects in Muscle and Nerve, held in Osaka, Japan, July 1994. It is an update of current literature, but also includes original data from the collaborating authors on mutations occurring in the lysosomal alpha-glucosidase gene and on prenatal diagnosis by chorionic villus sampling. The genotype-phenotype correlation and the prospects for therapy are addressed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603530     DOI: 10.1002/mus.880181414

Source DB:  PubMed          Journal:  Muscle Nerve Suppl


  28 in total

1.  [Diagnosis and differential diagnosis of lysosomal glycogen storage disease].

Authors:  D Fischer; S Paus; R Schröder
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 2.  Glycogen phosphorylation and Lafora disease.

Authors:  Peter J Roach
Journal:  Mol Aspects Med       Date:  2015-08-13

3.  Seven cases of Pompe disease from Greece.

Authors:  M Kroos; P Manta; I Mavridou; F Muntoni; D Halley; R Van der Helm; D Zaifeiriou; A Van der Ploeg; A Reuser; H Michelakakis
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

Review 4.  Role of autophagy in the pathogenesis of Pompe disease.

Authors:  N Raben; A Roberts; P H Plotz
Journal:  Acta Myol       Date:  2007-07

5.  Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.

Authors:  Cathryn S Mah; Darin J Falk; Sean A Germain; Jeffry S Kelley; Melissa A Lewis; Denise A Cloutier; Lara R DeRuisseau; Thomas J Conlon; Kerry O Cresawn; Thomas J Fraites; Martha Campbell-Thompson; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2010-01-26       Impact factor: 11.454

Review 6.  Challenges in treating Pompe disease: an industry perspective.

Authors:  Hung V Do; Richie Khanna; Russell Gotschall
Journal:  Ann Transl Med       Date:  2019-07

7.  Novel method for detection of glycogen in cells.

Authors:  Alexander V Skurat; Dyann M Segvich; Anna A DePaoli-Roach; Peter J Roach
Journal:  Glycobiology       Date:  2017-05-01       Impact factor: 4.313

8.  Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.

Authors:  J M Van den Hout; A J Reuser; J B de Klerk; W F Arts; J A Smeitink; A T Van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

9.  Improved efficacy of a next-generation ERT in murine Pompe disease.

Authors:  Su Xu; Yi Lun; Michelle Frascella; Anadina Garcia; Rebecca Soska; Anju Nair; Abdul S Ponery; Adriane Schilling; Jessie Feng; Steven Tuske; Maria Cecilia Della Valle; José A Martina; Evelyn Ralston; Russell Gotschall; Kenneth J Valenzano; Rosa Puertollano; Hung V Do; Nina Raben; Richie Khanna
Journal:  JCI Insight       Date:  2019-03-07

10.  Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy.

Authors:  A Broomfield; J Fletcher; J Davison; N Finnegan; M Fenton; A Chikermane; C Beesley; K Harvey; E Cullen; C Stewart; S Santra; S Vijay; M Champion; L Abulhoul; S Grunewald; A Chakrapani; M A Cleary; S A Jones; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2015-10-26       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.